Therapeutic Targets

The API Interacts with Therapeutic Targets
related to Overactive Innate Immunity

  • Inhibition of Neutrophil Activation with reduction in Neutrophil Extracellular Traps (NETs), limiting progression of arterial thrombosis in Acute Ischemic Stroke (AIS) and Acute Coronary Syndrome (ACS).
  • Inhibition of Fibrin accumulation in Thromboses, limiting acute and chronic damage in Traumatic Brain Injury and facilitating successful thrombectomy in Large Vessel Occlusion (LVO) AIS.
  • Inhibition of Extracellular Vesicle (EV) Release following TBI with protection of the Blood Brain Barrier (BBB) and prevention of post-traumatic cerebral edema.
  • Prevention of Microbleeding associated with TBI associated loss of integrity of the BBB.
Skip to content